Category: Diseases, Syndromes and Conditions

Human Transmission in 2019 Outbreak of Deadly Chapare Virus

In 2019, five people were infected and three died near the Bolivian capital La Paz by the Chapare virus. US Centers for Disease Control and Prevention (CDC) researchers detailed new clues to the mysterious disease that have recently been uncovered.

The Chapare virus is an arenavirus, like the deadly Lassa virus which, in West Africa, causes thousands of deaths every year. Similar to the Ebola virus, arenaviruses can produce a haemorrhagic fever, causing multiple organ damage. 

The researchers identified human transmission from patients to healthcare workers, and believe that blood, semen and other bodily fluids can transmit the disease.
Caitlin Cossaboom, DVM, PhD, MPH, an epidemiologist with the CDC’s Division of High-Consequence Pathogens and Pathology, said, “Our work confirmed that a young medical resident, an ambulance medic and a gastroenterologist all contracted the virus after encounters with infected patients–and two of these healthcare workers later died. We now believe many bodily fluids can potentially carry the virus.”

Viral DNA was found in the semen of one the survivors, raising the prospect of sexual transmission. Viral DNA was also found in rodents in the area, although the researchers cautioned that it did not necessarily represent a source. 

“The genome sequence of the RNA we isolated in rodent specimens matches quite well with what we have seen in human cases,” Cassaboom said.

By pooling resources, researchers were able to make rapid headway in identifying the disease. Gene sequencing technology quickly confirmed the virus as a match for the original 2004 outbreak.

Source: Eureka Alert

Major Cardiovascular Events Cut by Use of Polypills

Results presented in a late-breaking clinical trial presentation at the American Heart Association’s Scientific Sessions 2020 reported that large randomised trial demonstrated that a simple polypill (containing cholesterol and blood pressure control medication) could significantly reduce cardiovascular risk.

In the International Polycap Study (TIPS)-3, 5700 participants in 9 countries were given either the polypill, aspirin, the polypill plus aspirin or Vitamin D and monitored for five years for major cardiovascular events.

The polypill contained atenolol 100mg, ramipril 10mg, hydrochlorothiazide 25 mg, and simvastatin 40 mg.

The combination of polypill and aspirin reduced cardiovascular events by 31%, whilst aspirin alone had a 14% reduction and 21% with polypill alone.

Salim Yusuf, MD, BS, D Phil, co-author of the study said, “Aspirin should be prescribed with a polypill in primary prevention for patients at intermediate risk of heart disease. Our study results provide important data regarding the role of the polypill in preventing the development of heart disease.”

Source: News-Medical.Net

Weight Link to COVID Risk Emphasised by CDC

The Centers for Disease Control and Prevention (CDC) in the US has included in its coronavirus risk warning people who are considered overweight (a BMI of 25 to 29.9, obese is above 30).

Dr Donald Hensrud, director of the Mayo Clinic Healthy Living Program, explained that obesity already is associated with several complications – diabetes, high blood pressure, dyslipidaemia and cardiovascular disease.

Dr Hensrud said, “Now COVID-19 comes along, and we’ve got all the issues we had before plus some additional ones. Obesity is associated with low-grade inflammation and an effect on our immune system. This affects our susceptibility to COVID-19. People who are obese are more likely to develop COVID-19 and complications from it, including dying, than people who aren’t obese. In addition, people with diabetes and some of the other complications from obesity are also at increased risk. So obesity and its complications independently take the risks of COVID-19 and elevate them significantly.”

Dr Hensrud said that he noted patients of his had put on weight during lockdown due to comfort eating and staying at home without any exercise. In order to reduce their risk, people should resolve to eat a healthy diet and engage in exercise, although he cautioned that losing more than 10% body weight in six months can impact the immune system.

Source: Medical Xpress

Promising Drug May Worsen Instead of Treat Multiple Sclerosis

A drug, TEPP-46,  that is being assessed to treat multiple sclerosis (MS) may in fact be worsening the progression of the disease, wrote University of Virginia on the Medical Xpress website.

MS is a debilitating disease which affects over one million people in America, in which the immune system attacks the myelin sheath, creating a range of effects in sufferers, from muscle spasms to numbness.

Presently available drugs to treat MS often have unwanted side effects, such as weakening the immune system. Originally developed to fight cancer, TEPP-46 is small-molecule drug that targets the changes in cellular metabolism that occur in both cancer and MS. However, the drug has been shown to produce off-target effects. In the mouse model used by the researchers, the inflammation was directed away from the spinal cord and into the brain. The researchers believed that this was the result of the drug harmfully changing T cells, but could not explain why. 

“It was not at all what we expected,” said MS researcher Alban Gaultier, PhD, of University of Virginia. “The take-home message is that we should be very careful and do more fundamental research before we propose to take this to clinical trials.”

Vaping May Increase Respiratory Disease Risk

Research has increasingly been focused on the health effects of vaping, usually touted as a way to quit combustible smoking, and evidence is accumulating for their risks.

Research by Boston University School of Public Health and School of Medicine has revealed that, far from being harmless, vaping may in fact raise the risk for a number of respiratory diseases by 21% for former e-cigarette users and 43% for current users.

Corresponding author Dr Andrew Stokes, assistant professor of global health at Boston University said, “This provides some of the very first longitudinal evidence on the harms associated with e-cigarette products.

“In recent years we have seen dramatic increase in e-cigarette use among youth and young adults which threatens to reverse decades of hard-fought gains,” Stokes said. “This new evidence also suggests that we may see an increase in respiratory disease as youth and young adults age into midlife, including asthma, COPD, and other respiratory conditions.”

Previous research has largely focused on in vitro studies, or short-term studies with human participants. The study used data from 21 618 participants from the nationally representative Population Assessment of Tobacco and Health (PATH) survey. To isolate the effect of e-cigarettes, the researchers adjusted for any form of combustible smoking use, including second-hand smoking.

“With a longitudinal study design and extensive sensitivity analyses, the study adds to a growing body of evidence indicating long-term health risks of e-cigarette use to the respiratory system,” said study lead author Wubin Xie, a postdoctoral associate at Boston University.

Source: Medical Xpress